BR112021005271A2 - tratamento do colangiocarcinoma - Google Patents

tratamento do colangiocarcinoma Download PDF

Info

Publication number
BR112021005271A2
BR112021005271A2 BR112021005271-2A BR112021005271A BR112021005271A2 BR 112021005271 A2 BR112021005271 A2 BR 112021005271A2 BR 112021005271 A BR112021005271 A BR 112021005271A BR 112021005271 A2 BR112021005271 A2 BR 112021005271A2
Authority
BR
Brazil
Prior art keywords
fgfr
patient
fgfr2
inhibitor
mutants
Prior art date
Application number
BR112021005271-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacqueline Cirillo Bussolari
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021005271A2 publication Critical patent/BR112021005271A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112021005271-2A 2018-09-21 2019-09-19 tratamento do colangiocarcinoma BR112021005271A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734501P 2018-09-21 2018-09-21
US62/734,501 2018-09-21
PCT/EP2019/075222 WO2020058432A1 (en) 2018-09-21 2019-09-19 Treatment of cholangiocarcinoma

Publications (1)

Publication Number Publication Date
BR112021005271A2 true BR112021005271A2 (pt) 2021-06-15

Family

ID=68289904

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005271-2A BR112021005271A2 (pt) 2018-09-21 2019-09-19 tratamento do colangiocarcinoma

Country Status (15)

Country Link
US (1) US12133851B2 (cg-RX-API-DMAC7.html)
EP (1) EP3852756A1 (cg-RX-API-DMAC7.html)
JP (1) JP7761485B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210064274A (cg-RX-API-DMAC7.html)
CN (1) CN112739347A (cg-RX-API-DMAC7.html)
AU (1) AU2019342289A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005271A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190826A1 (cg-RX-API-DMAC7.html)
IL (1) IL281595A (cg-RX-API-DMAC7.html)
JO (1) JOP20210052A1 (cg-RX-API-DMAC7.html)
MA (1) MA53655A (cg-RX-API-DMAC7.html)
MX (1) MX2021003320A (cg-RX-API-DMAC7.html)
PH (1) PH12021550628A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102546XA (cg-RX-API-DMAC7.html)
WO (1) WO2020058432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19802377A1 (de) * 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CN114984013A (zh) * 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer
CA3100422A1 (en) * 2018-05-16 2019-11-21 Debiopharm International, S.A. Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3

Also Published As

Publication number Publication date
JP2022501355A (ja) 2022-01-06
JOP20210052A1 (ar) 2021-03-18
SG11202102546XA (en) 2021-04-29
WO2020058432A1 (en) 2020-03-26
EA202190826A1 (ru) 2021-06-16
EP3852756A1 (en) 2021-07-28
JP7761485B2 (ja) 2025-10-28
CA3111866A1 (en) 2020-03-26
PH12021550628A1 (en) 2022-02-14
CN112739347A (zh) 2021-04-30
IL281595A (en) 2021-05-31
MA53655A (fr) 2021-12-29
US12133851B2 (en) 2024-11-05
AU2019342289A1 (en) 2021-03-18
MX2021003320A (es) 2021-05-14
US20220054483A1 (en) 2022-02-24
KR20210064274A (ko) 2021-06-02

Similar Documents

Publication Publication Date Title
US11707463B2 (en) FGFR2 inhibitors for the treatment of cholangiocarcinoma
TWI817018B (zh) 用於治療braf相關的疾病和失調症之化合物
US10822312B2 (en) Substituted quinazoline compounds and methods of use
TWI706136B (zh) Fgfr突變基因組於鑑定對於fgfr抑制劑治療有反應之癌症患者的用途
RU2715236C2 (ru) Комбинации
KR20260047240A (ko) 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017092413A1 (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
Richters et al. Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design
JP2021072776A (ja) Ttk阻害剤化学療法の為の予後バイオマーカー
WO2020023921A1 (en) Treatments for mutations in acute myeloid leukemia
Lv et al. A potent SOS1 PROTAC degrader with synergistic efficacy in combination with KRASG12C inhibitor
TWI885019B (zh) 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物
EP4213852A1 (en) Non-invasive functional companion assays for oncogene targeted therapy for brain cancer
WO2022033575A1 (zh) 具有大环结构的含氟并杂环衍生物的应用
JP7761485B2 (ja) 胆管癌の処置
US20240190858A1 (en) Crystalline forms, pharmaceutical compositions and methods of use thereof
US9751838B2 (en) Tetrahydroquinoline derivatives and their use as Epac inhibitors
HK40029054A (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
US10851051B2 (en) Compositions and methods for treating multiple myeloma
HK40092752A (en) Companion diagnostic tool for mutant p53 reactivating compounds
Pricl et al. A new mutation affecting the ATP pocket of kit receptor in patients with GIST showing acquired resistance to Imatinib: a coupled experimental and modeling investigation
HK1235833B (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
BR122024005365A2 (pt) Métodos para a identificação de um paciente com câncer de bexiga que é responsivo ao tratamento com um inibidor do fgfr e kit
BR122024005360A2 (pt) Métodos para a identificação de um paciente com câncer de bexiga que é responsivo ao tratamento com um inibidor do fgfr e kit

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.